专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明授权

US09427461B2 TOPK peptides and vaccines including the same 有权
标题翻译： TOPK肽和疫苗包括相同的
公开(公告)号：US09427461B2
公开(公告)日：2016-08-30
申请号：US14353261
申请日：2012-10-25
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama
IPC分类号： A61K39/00 , C07K16/18 , C07K7/06 , G01N33/574 , C07K14/47 , G01N33/50 , C12N9/12 , A61K38/00
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/0005 , A61K2039/5154 , A61K2039/572 , C07K7/06 , C07K14/4748 , C07K16/18 , C07K16/40 , C07K2317/34 , C12N9/12 , C12N9/1205 , C12Y207/12002 , G01N33/505 , G01N33/574
摘要： The present invention provides isolated epitope peptides derived from TOPK and immunogenic fragments thereof have an ability to induce cytotoxic T lymphocytes (CTLs) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a TOPK-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have CTL inducibility. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical compositions of this invention find particular utility in either or both of the treatment and prevention of a number of cancers.
摘要翻译：本发明提供了源自TOPK的分离的表位肽，其免疫原性片段具有诱导细胞毒性T淋巴细胞（CTL）的能力，因此适用于癌症免疫治疗，更特别地，作为癌症疫苗。本发明的肽包括包括TOPK衍生的氨基酸序列和其修饰形式的两种肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，只要这些修饰版本具有CTL 诱导性。还提供了编码任何前述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物组合物。本发明的肽，多核苷酸和药物组合物在治疗和预防多种癌症中的任一者或两者中都具有特别的用途。

22. 发明申请

US20150374810A1 TOMM34 PEPTIDES AND VACCINES INCLUDING THE SAME 审中-公开
标题翻译： TOMM34肽和疫苗，包括它们
公开(公告)号：US20150374810A1
公开(公告)日：2015-12-31
申请号：US14810287
申请日：2015-07-27
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Osawa , Sachiko Yoshimura , Tomohisa Watanabe , Gaku Nakayama
IPC分类号： A61K39/00 , C12N5/0783 , C07K7/06
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , C07K14/705 , C12N5/0638 , C12N2501/998 , C12N2502/1114 , C12N2502/1121 , G01N33/57407
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.
摘要翻译：本发明提供分离的肽或衍生自SEQ ID NO：42的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。肽可以包括一个上述氨基酸序列中的一个，两个或几个氨基酸序列的取代，缺失或添加。本发明还提供包含这些肽的药物组合物。本发明的肽可用于治疗癌症。

23. 发明授权

US09132176B2 RAB6KIFL/KIF20A epitope peptide and vaccines containing the same 有权
标题翻译： RAB6KIFL / KIF20A表位肽和含有它们的疫苗
公开(公告)号：US09132176B2
公开(公告)日：2015-09-15
申请号：US14500877
申请日：2014-09-29
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Yasuharu Nishimura , Katsunori Imai , Yusuke Nakamura , Takuya Tsunoda
IPC分类号： A01K1/00 , A01K61/00 , A01K67/00 , A01K67/027 , A61K39/00 , C07K14/47 , C12N9/14 , A61K38/16
CPC分类号： A61K39/00 , A01K67/0278 , A01K2207/15 , A01K2217/052 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/03 , A01K2267/0387 , A61K38/16 , A61K39/0011 , A61K2039/5152 , A61K2039/5154 , A61K2039/5158 , A61K2039/55 , A61K2039/572 , A61K2039/585 , C07K14/47 , C07K14/4748 , C12N9/14 , C12N2799/027 , C12Y306/04004
摘要： The present invention provides oligopeptides comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5. The present invention also provides a pharmaceutical composition containing the amino acid sequence of selected from the group consisting of SEQ ID NOs: 3, 4 and 5 formulated for the treatment or prevention of cancer in a subject. Furthermore, the present invention provides a method of inducing immune response using such oligopeptides and pharmaceutical agents.
摘要翻译：本发明提供了包含选自SEQ ID NO：3,4和5的氨基酸序列的寡肽。本发明还提供含有选自SEQ ID NO：3,4和5的氨基酸序列的药物组合物。 3，4和5配制用于治疗或预防受试者的癌症。此外，本发明提供使用这种寡肽和药剂诱导免疫应答的方法。

24. 发明授权

US09073968B2 FOXM1 peptide and medicinal agent comprising the same 有权
标题翻译： FOXM1肽及其药剂
公开(公告)号：US09073968B2
公开(公告)日：2015-07-07
申请号：US14036879
申请日：2013-09-25
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Yasuharu Nishimura , Kazunori Yokomine , Takuya Tsunoda , Yusuke Nakamura
IPC分类号： A61K38/00 , C07K7/08 , A61K39/00 , C12N5/0783
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/06 , C07K7/08 , C12N5/0636 , C12N5/0638 , C12N2501/998 , C12N2502/11
摘要： An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.
摘要翻译：本发明的目的是提供一种能够通过鉴定可以激活癌细胞破坏性的FOXM1衍生的肽来靶向大约30％的高度表达日本人中的叉头盒M1（FOXM1）的各种癌症患者的癌症免疫治疗的手段人类杀伤T细胞通过结合HLA-A2。本发明提供下述（A）或（B）的肽：（A）包含SEQ ID NO：1〜3中任一项所述的氨基酸序列的肽; （B）包含SEQ ID NO：1至3中任一项的氨基酸序列的肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，并且其中肽显示出细胞毒性（杀伤）T细胞诱导活性。

25. 发明授权

US09453025B2 Tricyclic compounds and PBK inhibitors containing the same 有权
公开(公告)号：US09453025B2
公开(公告)日：2016-09-27
申请号：US14565047
申请日：2014-12-09
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Yusuke Nakamura , Yo Matsuo , Shoji Hisada , Feryan Ahmed , Raymond Huntley , Zohreh Sajjadi-Hashemi , David M. Jenkins , Robert B. Kargbo , Wenge Cui , Polivina Jolicia F. Gauuan , Joel R. Walker , Helene Decornez , Mahender Gurram
IPC分类号： A61K31/44 , A61K31/38 , C07D455/04 , C07D333/50 , C07D495/04 , C07D221/06 , C07D487/04 , C07D513/04 , C07D221/16 , C07D401/10 , C07D213/64 , C07D401/04 , C07D519/00
CPC分类号： C07D495/04 , C07D213/64 , C07D221/06 , C07D221/16 , C07D401/04 , C07D401/10 , C07D487/04 , C07D513/04 , C07D519/00
摘要： Tricyclic compounds are provided. These compounds are PBK inhibitors, and are useful for the treatment of PBK related diseases, including cancer.

26. 发明授权

US09446106B2 NEIL3 peptides and vaccines including the same 有权
公开(公告)号：US09446106B2
公开(公告)日：2016-09-20
申请号：US14689302
申请日：2015-04-17
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe , Yusuke Nakamura , Yoichi Furukawa
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , A61K39/39 , C12N9/88
CPC分类号： C07K14/4748 , A61K39/00 , A61K39/0011 , A61K39/39 , A61K2039/53 , A61K2039/572 , C12N9/88 , C12Y402/99018 , Y02A50/396
摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

27. 发明授权

US09403890B2 HJURP peptides and vaccines including the same 有权
标题翻译： HJURP肽和疫苗包括相同
公开(公告)号：US09403890B2
公开(公告)日：2016-08-02
申请号：US14205163
申请日：2014-03-11
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： C07K7/00 , A61K38/08 , C07K14/47 , C07K7/06 , C07K16/18 , A61K35/12 , A61K38/00 , A61K39/00
CPC分类号： C07K14/4748 , A61K35/12 , A61K38/00 , A61K39/00 , C07K7/06 , C07K16/18
摘要： Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding the peptides as well as pharmaceutical agents, substances and/or compositions that include any of the peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find utility in the treatment of cancers, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.
摘要翻译：本文描述了衍生自SEQ ID NO：50的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗。本发明的肽包括上述氨基酸序列及其修饰形式，只要它们保留原始序列所需的细胞毒性T细胞诱导能力即可。还提供了编码肽的核酸以及包括任何肽或核酸的药剂，物质和/或组合物。本发明的肽，核酸，药物，物质和组合物可用于治疗癌症，包括例如AML，膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌，食道癌，扩散型胃癌，肝癌，NSCLC，淋巴瘤，骨肉瘤，卵巢癌，胰腺癌，前列腺癌，肾癌，SCLC，软组织肿瘤和睾丸肿瘤。

28. 发明申请

US20150265689A1 FOXM1 PEPTIDE AND MEDICINAL AGENT COMPRISING THE SAME 审中-公开
标题翻译： FOXM1肽和药物包括它们
公开(公告)号：US20150265689A1
公开(公告)日：2015-09-24
申请号：US14729752
申请日：2015-06-03
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Yasuharu Nishimura , Kazunori Yokomine , Takuya Tsunoda , Yusuke Nakamura
IPC分类号： A61K39/00 , C12N5/0783 , C07K7/06
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/06 , C07K7/08 , C12N5/0636 , C12N5/0638 , C12N2501/998 , C12N2502/11
摘要： An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.
摘要翻译：本发明的目的是提供一种能够通过鉴定可以激活癌细胞破坏性的FOXM1衍生的肽来靶向大约30％的高度表达日本人中的叉头盒M1（FOXM1）的各种癌症患者的癌症免疫治疗的手段人类杀伤T细胞通过结合HLA-A2。本发明提供下述（A）或（B）的肽：（A）包含SEQ ID NO：1〜3中任一项所述的氨基酸序列的肽; （B）包含SEQ ID NO：1至3中任一项的氨基酸序列的肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，并且其中肽显示出细胞毒性（杀伤）T细胞诱导活性。

29. 发明授权

US08846038B2 Method for treating synovial sarcoma 有权
公开(公告)号：US08846038B2
公开(公告)日：2014-09-30
申请号：US13918599
申请日：2013-06-14
申请人： Oncotherapy Science, Inc.
发明人： Yusuke Nakamura , Toyomasa Katagiri , Chikako Fukukawa , Motoki Kuhara
IPC分类号： A61K39/395 , C12Q1/68 , C07K16/28
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/28 , C07K2317/34 , C07K2317/732 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/136
摘要： Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.

30. 发明申请

US20140023672A1 FOXM1 PEPTIDE AND MEDICINAL AGENT COMPRISING THE SAME 审中-公开
标题翻译： FOXM1肽和药物包括它们
公开(公告)号：US20140023672A1
公开(公告)日：2014-01-23
申请号：US14036879
申请日：2013-09-25
申请人： ONCOTHERAPY SCIENCE, INC.
发明人： Yasuharu Nishimura , Kazunori Yokomine , Takuya Tsunoda , Yusuke Nakamura
IPC分类号： C07K7/08
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K7/06 , C07K7/08 , C12N5/0636 , C12N5/0638 , C12N2501/998 , C12N2502/11
摘要： An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below:(A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.
摘要翻译：本发明的目的是提供一种能够通过鉴定可以激活癌细胞破坏性的FOXM1衍生的肽来靶向大约30％的高度表达日本人中的叉头盒M1（FOXM1）的各种癌症患者的癌症免疫治疗的手段人类杀伤T细胞通过结合HLA-A2。本发明提供下述（A）或（B）的肽：（A）包含SEQ ID NO：1〜3中任一项所述的氨基酸序列的肽; （B）包含SEQ ID NO：1至3中任一项的氨基酸序列的肽，其中一个，两个或几个氨基酸被取代，缺失，插入和/或添加，并且其中肽显示出细胞毒性（杀伤）T细胞诱导活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式